for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biogen Inc

BIIB.O

Latest Trade

241.75USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

223.25

 - 

374.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
241.75
Open
--
Volume
--
3M AVG Volume
35.10
Today's High
--
Today's Low
--
52 Week High
374.99
52 Week Low
223.25
Shares Out (MIL)
153.88
Market Cap (MIL)
37,200.88
Forward P/E
7.20
Dividend (Yield %)
--

Next Event

Q4 2020 Biogen Inc Earnings Release

Latest Developments

More

European Medicines Agency Accepts Biogen’S Aducanumab Marketing Authorization Application For Alzheimer's Disease

Biogen Inc Says Third Quarter Revenue $3,376 Million

Biogen Announces New $5.0 Billion Share Repurchase Authorization

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Industry

Biotechnology & Drugs

Contact Info

225 Binney St

CAMBRIDGE, MA

02142-1031

United States

+1.781.4642000

https://www.biogen.com/

Executive Leadership

Stelios B. Papadopoulos

Independent Chairman of the Board

Michel Vounatsos

Chief Executive Officer, Director

Michael R. McDonnell

Chief Financial Officer, Executive Vice President

Ginger Gregory

Chief Human Resource Officer, Executive Vice President

Susan H. Alexander

Executive Vice President, Chief Legal Officer and Secretary

Key Stats

2.68 mean rating - 34 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

12.3K

2018

13.5K

2019

14.4K

2020(E)

13.4K
EPS (USD)

2017

21.810

2018

26.200

2019

33.570

2020(E)

33.582
Price To Earnings (TTM)
8.00
Price To Sales (TTM)
2.61
Price To Book (MRQ)
3.46
Price To Cash Flow (TTM)
6.59
Total Debt To Equity (MRQ)
69.02
LT Debt To Equity (MRQ)
69.02
Return on Investment (TTM)
23.39
Return on Equity (TTM)
19.72

Latest News

Latest News

Merck KGaA lifts earnings guidance on demand for lab tools

Healthcare and chemicals group Merck KGaA <MRCG.DE> lifted its guidance for full year earnings after the scramble to ready treatments and vaccines against the coronavirus bolstered demand for its supplies for biotech labs.

Biogen plunges 30% after FDA panel votes against Alzheimer's drug

Biogen Inc's <BIIB.O> shares slumped about 30% on Monday as the drugmaker's chances of getting a regulatory approval for its experiment Alzheimer's treatment suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine.

Combative U.S. FDA panel votes against Biogen Alzheimer's drug

A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted that a potential Alzheimer’s treatment from Biogen Inc has not been proven to slow progression of the disease, a sharp rebuke to agency staff who earlier this week praised the drug.

UPDATE 1-U.S. FDA panel votes successful study on Biogen Alzheimer's drug cannot stand alone

A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted that one of two large studies on Biogen Inc's experimental Alzheimer's disease drug cannot be viewed alone without regard for the other failed trial.

FDA advisory panel convenes to discuss whether Biogen Alzheimer's drug should be approved

A meeting of outside advisers to the U.S. Food and Drug Administration convened on Friday to discuss whether to recommend approval of Biogen Inc's experimental Alzheimer's disease drug aducanumab.

Biogen Alzheimer's drug closer to approval with U.S. FDA staff backing, shares jump 40%

Biogen Inc has shown "exceptionally persuasive" evidence that its experimental Alzheimer's disease drug is effective, U.S. Food and Drug Administration staff said on Wednesday, elevating its chances of a swift approval and sending company shares soaring.

U.S. experts to review Biogen drug that could be first new Alzheimer's treatment in decades

U.S. health experts this week will decide whether to recommend approval for Biogen Inc's <BIIB.O> Alzheimer's drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if it works.

UPDATE 1-EMA to review Biogen's aducanumab drug for Alzheimer's

Biogen Inc and Eisai Co Ltd said on Friday the European health regulator has accepted for review the marketing application for their closely watched experimental Alzheimer's treatment aducanumab.

EMA accepts Biogen's Alzheimer's treatment aducanumab for review

Biogen Inc and partner Eisai Co Ltd said on Friday the European health regulator has accepted for review the marketing application for its closely-watched experimental Alzheimer's treatment aducanumab.

UPDATE 3-Biogen readies for U.S. launch of Alzheimer's drug ahead of FDA meeting

Biogen Inc said on Wednesday it was diverting part of its budget and resources for blockbuster multiple sclerosis drug Tecfidera towards a potential launch of its Alzheimer's disease drug, aducanumab.

BRIEF-Biogen Says U.S. FDA Decision On Aducanumab Would Influnce Other Regulators: Conf. Call

* BIOGEN INC CEO SAYS UPCOMING FDA PANEL MEETING FOR ADUCANUMAB IS CO'S HIGHEST PRIORITY: CONF. CALL

Biogen, gene-editing startup Scribe to develop therapies for Lou Gehrig's disease

U.S. drugmaker Biogen Inc and gene-editing startup Scribe Therapeutics Inc will jointly develop therapies for treating underlying genetic causes of amyotrophic lateral sclerosis (ALS), a fatal neurological disorder better known as Lou Gehrig's disease.

Alzheimer's drug from Biogen to get speedy U.S. review

The U.S. Food and Drug Administration will conduct an expedited review of an experimental Alzheimer's drug from Biogen Inc and Japan's Eisai Co Ltd, the companies said on Friday, the first application in 17 years to be reviewed by the agency for a treatment of the mind-robbing...

U.S. FDA accepts Biogen's marketing application for Alzheimer's drug

Biogen Inc and Japan's Eisai Co Ltd said on Friday the U.S. Food and Drug Administration has accepted their marketing application for experimental Alzheimer's disease treatment aducanumab.

Biogen lifts full-year profit forecast as Tecfidera boosts quarter

Biogen Inc <BIIB.O> raised its 2020 earnings forecast on Wednesday after better-than-expected sales of its multiple sclerosis treatment Tecfidera helped the drugmaker beat second-quarter profit estimates.

CORRECTED-UPDATE 1-Biogen raises full-year profit view, quarter boosted by Tecfidera demand

Drugmaker Biogen Inc beat analysts' estimates for quarterly profit on Wednesday on better-than-expected sales of its multiple sclerosis treatment Tecfidera, and boosted its 2020 profit outlook.

Biogen profit rises 3.2% on demand for multiple sclerosis drug

Biogen Inc reported a 3.2% rise in second-quarter profit on Wednesday, getting a lift from demand for its top-selling multiple sclerosis drug Tecfidera.

Biogen names IQVIA's Michael McDonnell CFO

Biogen Inc on Tuesday named IQVIA Holding Inc's Michael McDonnell as chief financial officer, effective Aug. 15.

Biogen to study Spinraza in combination with $2 million Novartis drug

One of medicine's costliest treatment areas could become even more pricey as Biogen <BIIB.O> seeks to layer its $750,000 spinal muscular atrophy drug on top of $2.1 million (1.66 million pounds)-per-patient Novartis <NOVN.S> gene therapy Zolgensma.

Novartis says Zolgensma patients kept gains as Biogen eyes follow-up trial

Novartis <NOVN.S> Chief Executive Vas Narasimhan said spinal muscular atrophy patients who got the Swiss drugmaker's Zolgensma maintained improvements, a response to Biogen's <BIIB.O> plan to test its drug Spinraza after Zolgensma treatment.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up